A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been shown to be efficacious in reducing mortality and heart failure hospitalizations in patients with heart failure and reduced ejection fraction. However, their role in patients with heart failure and preserved ejection fraction (HFpEF) is still unclear. Recently, the results of the EMPEROR-Preserved trial (Empagliflozin in Heart Failure with a Preserved Ejection Fraction) were released and it was the first randomized controlled trial (RCT) evaluating SGLT-2 inhibitors exclusively in patients with HFpEF. 1 Anker SD Butler J Filippatos G Ferreira JP Bocchi E Böhm M Brunner-La Rocca HP Choi DJ Chopra V Chuquiure-Valenzuela E Giannetti N Gomez-Mesa JE Janssens S Januzzi JL Gonzalez-Juanatey JR Merkely B Nicholls SJ Perrone SV Piña IL Ponikowski P Senni M Sim D Spinar J Squire I Taddei S Tsutsui H Verma S Vinereanu D Zhang J Carson P Lam CSP Marx N Zeller C Sattar N Jamal W Schnaidt S Schnee JM Brueckmann M Pocock SJ Zannad F Packer M EMPEROR-Preserved Trial InvestigatorsEmpagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385: 1451-1461 Crossref PubMed Scopus (461) Google Scholar However, there have been other studies that have looked at the efficacy of SGLT-2 inhibitors in other populations that included HFpEF patients. Here, we conducted a meta-analysis to evaluate the efficacy of SGLT-2 inhibitors in patients with HFpEF by pooling the results of EMPEROR-Preserved trial with data from post hoc analyses of other trials.